School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, China.
Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Biomed Pharmacother. 2019 Mar;111:60-67. doi: 10.1016/j.biopha.2018.12.066. Epub 2018 Dec 18.
Calanthe fimbriata is a Tujia ethnic medicine with various medicinal value and it is traditionally used for the treatment of gastric ulcer, chronic hepatitis, pharyngitis, and so on.
The current study was conducted to evaluate the antidiabetic activity of C. fimbriata methanol extract (CfME) in oral glucose tolerance test (OGTT) mice and in streptozotocin (STZ)-induced diabetic mice.
Experimental diabetes was induced by intraperitoneal injection of STZ (60 mg/kg) for three consecutive days in mice. OGTT in mice and α-glucosidase inhibition assay were also adopted to investigate the activity and elucidate the mechanism of action. Gliclazide and metformin were used as standard drugs in OGTT mice and in STZ-induced diabetic mice experiments, respectively. Blood glucose, total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatic glycogen were measured in plasma or in livers.
CfME exerted potently antihyperglycemic activity in OGTT mice and in STZ-induced diabetic mice and decreased ALT, AST and TG levels, improved hepatomegaly, and increased hepatic glycogen content, however, CfME failed to modify the normal blood glucose in normoglycemic mice and exhibited weakly inhibitory activity on intestinal α-glucosidase.
The present study demonstrated that CfME exerted potently antidiabetic activity by restoring the liver function to increase the synthesis of hepatic glycogen and by improving insulin resistance of peripheral tissues to enhance the uptake and utilization of glucose.
手参是一种土家族民族药物,具有多种药用价值,传统上用于治疗胃溃疡、慢性肝炎、咽炎等。
本研究旨在评价手参甲醇提取物(CfME)在口服葡萄糖耐量试验(OGTT)小鼠和链脲佐菌素(STZ)诱导的糖尿病小鼠中的抗糖尿病活性。
采用连续 3 天腹腔注射 STZ(60mg/kg)的方法诱导实验性糖尿病。还采用 OGTT 实验和α-葡萄糖苷酶抑制实验来研究 CfME 的活性和作用机制。在 OGTT 实验和 STZ 诱导的糖尿病实验中,格列齐特和二甲双胍分别作为标准药物。测量血浆或肝脏中的血糖、总胆固醇(TC)、甘油三酯(TG)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)和肝糖原。
CfME 在 OGTT 实验和 STZ 诱导的糖尿病实验中表现出很强的降血糖活性,降低了 ALT、AST 和 TG 水平,改善了肝肿大,并增加了肝糖原含量,但 CfME 未能改变正常血糖的正常小鼠,对肠道α-葡萄糖苷酶表现出较弱的抑制活性。
本研究表明,CfME 通过恢复肝功能增加肝糖原的合成,以及通过改善外周组织的胰岛素抵抗来增强葡萄糖的摄取和利用,从而发挥强大的抗糖尿病活性。